Abstract
Diabetes, a metabolic disorder is alarmingly increasing across the globe and currently ample of research is being carriedout to treat hyperglycaemia and its secondary complications in diabetic patients. Despite extensive research, specificcauses of this metabolic disorder are still not well understood at molecular level. As p53 a tumor suppressor gene hasmostly been associated with cancer, however, the most recent research studies sheds light on vital role of p53 signallingin diabetes development. In this review we underline the role of altered p53 protein expression in diabetes and itsassociated metabolic disorders including hypertension and dyslipidemia. We try to throw some light on latest studies thatsuggest how p53 signalling may act as a new potential therapeutic target for diabetes and its related metabolic disorders.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
